NASDAQ
0.09USD
-0.03 (-24.84%)
We have scored 12 news catalysts on Novan, Inc. (NOVN) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.31). Most of the impact sits in sector healthcare and pricing power structural.
Market cap
2.6M
P/E
—
EPS
—
Beta
-0.04
52W range
0.082-3.33
Day range
0.08–0.14
Open
0.14
Prev close
0.13
Volume
6.9M
Avg volume
1.2M
Dividend
0.00
Suppliers, customers, partners and competitors of Novan, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for NOVN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
IPO
2016-09-21
No scored catalysts in the window yet.
Show more NOVN articles →Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Novan, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
